Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy

详细信息    查看全文

• 作者：Carole Vuillerot ; MD ; PhD^a ; ^b ; ^c ; ^d ; ^{carole.vuillerot@chu-lyon.fr" class="auth_mail" title="E-mail the corresponding author} ; Christine Payan ; MD^e ; Jean Iwaz ; PhD^b ; ^c ; ^d ; ^f ; René ; Ecochard ; MD ; PhD^b ; ^c ; ^d ; ^f ; Carole Bé ; rard ; MD^a ; MFM Spinal Muscular Atrophy Study Group
• 关键词：Clinical trial ; Mobility limitation ; Muscle weakness ; Muscular atrophy ; spinal ; Neuromuscular diseases ; Rehabilitation
• 刊名：Archives of Physical Medicine and Rehabilitation
• 出版年：2013
• 出版时间：August 2013
• 年：2013
• 卷：94
• 期：8
• 页码：1555-1561
• 全文大小：184 K

文摘

To assess the ability of the Motor Function Measure (MFM) to detect changes in the progression of spinal muscular atrophy (SMA).

Design

Observational, retrospective, multicenter cohort study.

Setting

Seventeen departments of pediatric physical medicine.

Participants

Volunteer patients with SMA (N=112) aged 5.7 to 59 years with no treatment other than physical therapy and nutritional or respiratory assistance.

Interventions

Not applicable.

Main Outcome Measures

The distributions of the MFM scores (total score and 3 subscores) were analyzed per SMA subtype. The relationships between scores and age were studied. The slopes of score changes (reflecting MFM responsiveness) were estimated in patients with at least 6 months' follow-up and 2 MFMs. Hypothetical sample sizes for specific effect sizes in clinical trial scenarios are given.

Results

In 12 patients with SMA type 2 and 19 with SMA type 3 (mean ± SD follow-up, 25.8±19mo), there was a moderate inverse relationship between age and the MFM total score. Patients with less than 6 months' follow-up showed little score changes. Patients with longer follow-ups showed a slow deterioration (−0.9 points/y for type 2 and −0.6 points/y for type 3). Substantial responsiveness was obtained with the MFM Dimension 2 subscore (proximal and axial motricity) in patients with SMA type 2 (standardized response mean [SRM]=1.29), and with the MFM Dimension 1 subscore (standing and transfers) in patients with SMA type 3 aged 10 to 15 years (SRM=.94).

Conclusions

If further confirmed by larger studies, these preliminary results on the relative responsiveness of the MFM in SMA will foster its use in monitoring disease progression in patients who participate in clinical trials.